Statin potency, LDL receptors and new onset diabetes

Current Vascular Pharmacology

Volumn 12, Issue 5, 2014, Pages 739-740

  Athyros, Vasilios G ^a   Katsiki, Niki ^a   Karagiannis, Asterios ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALIROCUMAB; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; COLESEVELAM; EVOLOCUMAB; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; SERINE PROTEINASE; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CALORIC INTAKE; DIABETES MELLITUS; DRUG COST; DRUG EFFICACY; DRUG POTENCY; DYSLIPIDEMIA; EDITORIAL; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; META ANALYSIS (TOPIC); RISK ASSESSMENT; RISK BENEFIT ANALYSIS; METABOLISM;

DIABETES MELLITUS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RECEPTORS, LDL;

EID: 84918840697     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161112666140819110429     Document Type: Editorial

References (23)

1. Athyros VG, Mikhailidis DP. Pharmacotherapy: statins and new-onset diabetes mellitus-a matter for debate. Nat Rev Endocrinol 2012; 8: 133-4.
2. Dormuth CR, Filion KB, Paterson JM, et al. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ 2014; 348: g3244.
3. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011; 305: 2556-64.
4. Athyros VG, Mikhailidis DP. Therapy: Caloric and fat intake in statin users. Nat Rev Endocrinol 2014; 10: 450-1.
5. Besseling J, Hutten BA, Kastelein JJP, Hovingh GK. Lack of LDL-receptors protects against new onset type 2 diabetes-results of a cohort of 38, 000 individuals analyzed for FH mutations. Atherosclerosis 2014; 235: e15.
6. Brault M, Ray J, Gomez YH, Mantzoros CS, Daskalopoulou SS. Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metabolism 2014; 63: 735-45.
7. Sheng Z, Otani H, Brown MS, Goldstein JL. Independent regulation of sterol regulatory element-binding proteins 1 and 2 in hamster liver. Proc Natl Acad Sci USA 1995; 92: 935-8.
8. Liu TF, Tang JJ, Li PS, et al. Ablation of gp78 in liver improves hyperlipidemia and insulin resistance by inhibiting SREBP to decrease lipid biosynthesis. Cell Metab 2012; 16: 213-25.
9. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Lipid-lowering agents and new onset diabetes mellitus. Expert Opin Pharmacother 2010; 11: 1965-70.
10. Zhang L, McCabe T, Condra JH. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes. Int J Biol Sci 2012; 8: 310-27.
11. Cicero AF, Tartagni E, Ertek S. Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data. Expert Opin Drug Saf 2014; 13: 1023-30.
12. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Hypolipidaemic drug treatment: Yesterday is not gone yet, today is challenging and tomorrow is coming soon; let us combine them all. Curr Pharm Des 2014 Jun 20. [Epub ahead of print].
13. Mikhailidis DP, Athyros VG. Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics. Nat Rev Cardiol 2014; 11: 72-4.
14. Dong B, Singh AB, Fung C, Kan K, Liu J. CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism. Atherosclerosis 2014; 235: 449-62.
15. Krysiak R, Zmuda W, Okopien B. The effect of ezetimibe on androgen production in hypercholesterolemic women with polycystic ovary syndrome. Cardiovasc Ther 2014 Jul 23. doi: 10. 1111/1755-5922. 12088. [Epub ahead of print].
16. Tsunoda T, Nozue T, Yamada M, Mizuguchi I, Sasaki M, Michishita I. Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance. Diabetes Res Clin Pract 2013; 100: 46-52.
17. Lioudaki E, Ganotakis ES, Mikhailidis DP. Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years. Curr Vasc Pharmacol 2011; 9: 62-86.
18. Park H, Shima T, Yamaguchi K, et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 101-7.
19. Nozue T, Michishita I, Mizuguchi I. Effects of ezetimibe on glucose metabolism in patients with type 2 diabetes: A 12-week, open-label, uncontrolled, pilot study. Curr Ther Res Clin Exp 2010; 71: 252-8.
20. Takeshita Y, Takamura T, Honda M, et al. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia 2014; 57: 878-90.
21. Muraoka T, Aoki K, Iwasaki T, et al. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet. Metabolism 2011; 60: 617-28.
22. Nwose OM, Jones MR. Atypical mechanism of glucose modulation by colesevelam in patients with type 2 diabetes. Clin Med Insights Endocrinol Diabetes 2013; 6: 75-9.
23. Tziomalos K, Karagiannis A, Mikhailidis DP, Athyros VG. Colesevelam: a new and improved bile acid sequestrant? Curr Pharm Des 2013; 19: 3115-23.